rofecoxib has been researched along with Adenocarcinoma in 11 studies
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We tested whether long-term use of specific COX-2 inhibitors regress gastric IM." | 6.72 | Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. ( Auyeung, AC; Chan, FK; Chan, KF; Chan, WY; Lam, CC; Lau, JY; Leung, WK; Ng, EK; Sung, JJ, 2006) |
| "This study was aimed to compare the effects of three kinds of selective cyclooxygenase-2 inhibitors (meloxicam, celecoxib, rofecoxib on the growth of gastric adenocarcinoma SGC7901 cell line, and to observe the effect of rofecoxib, on transplanted gastric cancer of nude mice in vivo." | 3.72 | [The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma]. ( Liu, C; Tang, C; Wan, X; Wang, C; Zhou, X, 2003) |
| "Two esophageal adenocarcinoma cell lines (SEG-1 and BIC) and two esophageal squamous cell cancer lines (KYSE 150 and KYSE 410) were treated with rofecoxib at doses ranging from 8." | 3.72 | Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). ( Jackson, BJ; McFadden, DW; Riggs, DR; Vona-Davis, L, 2004) |
| " We tested whether long-term use of specific COX-2 inhibitors regress gastric IM." | 2.72 | Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. ( Auyeung, AC; Chan, FK; Chan, KF; Chan, WY; Lam, CC; Lau, JY; Leung, WK; Ng, EK; Sung, JJ, 2006) |
| "The BGC-823 gastric cancer cell line was incubated for 48 h with 0." | 1.36 | Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells. ( Chen, XM; Huang, ZG; Wang, ZR; Zhang, DW; Zhang, X; Zhu, FS, 2010) |
| "To study the effects of two specific cyclooxygenase inhibitors (SCI), rofecoxib and celecoxib, combined with chemotherapeutic drugs 5-Fu, DDP and VP-16 on gastric cancer cell line BGC-823, and to evaluate whether specific cyclooxygenase inhibitors can be used as a synergetic agent in chemotherapy." | 1.34 | [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro]. ( Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS, 2007) |
| "Rofecoxib could inhibit the activity of cyclooxygenase-2 in the tissue of gastric adenocarcinomas of nude mice." | 1.32 | Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. ( Liu, C; Tang, C; Wang, C; Zhou, X, 2004) |
| "Carcinogenesis in Barrett's esophagus (BE) is associated with an increased expression of cyclooxygenase (COX) 2." | 1.31 | Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. ( Anderson, MA; Burgart, LJ; Buttar, NS; Krishnadath, KK; Leontovich, O; Lutzke, LS; Pacifico, RJ; Wang, KK; Westcott, JY, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, FS | 2 |
| Chen, XM | 2 |
| Huang, ZG | 1 |
| Wang, ZR | 1 |
| Zhang, DW | 1 |
| Zhang, X | 2 |
| Liu, C | 2 |
| Tang, C | 2 |
| Wan, X | 1 |
| Wang, C | 2 |
| Zhou, X | 2 |
| Vona-Davis, L | 1 |
| Riggs, DR | 1 |
| Jackson, BJ | 1 |
| McFadden, DW | 1 |
| Peluffo, GD | 1 |
| Stillitani, I | 1 |
| Rodríguez, VA | 1 |
| Diament, MJ | 1 |
| Klein, SM | 1 |
| Noguera Aguilar, JF | 1 |
| Amengual Antich, I | 1 |
| Morón Canis, JM | 1 |
| Plaza Martínez, A | 1 |
| Martínez Córcoles, JA | 1 |
| Tortajada Collado, C | 1 |
| Pujol Tugores, JJ | 1 |
| Fei, SJ | 1 |
| Xiao, SD | 1 |
| Peng, YS | 1 |
| Chen, XY | 1 |
| Shi, Y | 1 |
| Leung, WK | 1 |
| Ng, EK | 1 |
| Chan, FK | 1 |
| Chan, WY | 1 |
| Chan, KF | 1 |
| Auyeung, AC | 1 |
| Lam, CC | 1 |
| Lau, JY | 1 |
| Sung, JJ | 1 |
| Gridelli, C | 1 |
| Gallo, C | 1 |
| Ceribelli, A | 1 |
| Gebbia, V | 1 |
| Gamucci, T | 1 |
| Ciardiello, F | 1 |
| Carozza, F | 1 |
| Favaretto, A | 1 |
| Daniele, B | 1 |
| Galetta, D | 1 |
| Barbera, S | 1 |
| Rosetti, F | 1 |
| Rossi, A | 1 |
| Maione, P | 1 |
| Cognetti, F | 1 |
| Testa, A | 1 |
| Di Maio, M | 1 |
| Morabito, A | 1 |
| Perrone, F | 1 |
| Wang, YJ | 1 |
| Feng, JX | 1 |
| Buttar, NS | 1 |
| Wang, KK | 1 |
| Leontovich, O | 1 |
| Westcott, JY | 1 |
| Pacifico, RJ | 1 |
| Anderson, MA | 1 |
| Krishnadath, KK | 1 |
| Lutzke, LS | 1 |
| Burgart, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II-III, Factorial Multicenter Randomized Trial Evaluating the Addition of Rofecoxib to Polycht With Cispatin and Gemcitabine and Fixed Dose Rate Infusion of Gem in Association With Cisplatin in 1st-line for Advanced NSCLC[NCT00385606] | Phase 2/Phase 3 | 400 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for rofecoxib and Adenocarcinoma
| Article | Year |
|---|---|
Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Double-Blind Method; Drug Administration Schedule; Follow-Up | 2006 |
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 2007 |
9 other studies available for rofecoxib and Adenocarcinoma
| Article | Year |
|---|---|
Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplat | 2010 |
[The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma].
Topics: Adenocarcinoma; Animals; Cell Division; Cyclooxygenase Inhibitors; Humans; Lactones; Mice; Mice, Inb | 2003 |
Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Topics: Adenocarcinoma; Apoptosis; Cell Division; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cycl | 2004 |
Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cell Survival; Chem | 2004 |
Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 2004 |
Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat.
Topics: Adenocarcinoma; Adenoma; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Car | 2005 |
Chemopreventive effects of rofecoxib and folic acid on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Body Weight; Cell Proliferation; Folic Acid; Gastr | 2006 |
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; | 2007 |
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxyg | 2002 |